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Abstract
Stimuli-triggered drug delivery systems are primarily focused on the applications of the tumor 
microenvironmental or cellular physiological cues to enhance the release of drugs at the target site. 
In this study, we applied adenosine-5′-triphosphate (ATP), the primary “energy molecule”, as a 
trigger for enhanced release of preloaded drugs responding to the intracellular ATP concentration 
that is significantly higher than the extracellular level. A new ATP-responsive anticancer drug 
delivery strategy utilizing DNA-graphene crosslinked hybrid nanoaggregates as carriers was 
developed for controlled release of doxorubicin (DOX), which consists of graphene oxide (GO), 
two single-stranded DNA (ssDNA, denoted as DNA1 and DNA2) and ATP aptamer. The single-
stranded DNA1 and DNA2 together with the ATP aptamer serve as the linkers upon hybridization 
for controlled assembly of the DNA-GO nanoaggregates, which effectively inhibited the release of 
DOX from the GO nanosheets. In the presence of ATP, the responsive formation of the ATP/ATP 
aptamer complex causes the dissociation of the aggregates, which promoted the release of DOX in 
the environment with a high ATP concentration such as cytosol compared with that in the ATP-
deficient extracellular fluid. This supports the development of a novel ATP-responsive platform 
for targeted on-demand delivery of anticancer drugs inside specific cells.
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Stimuli-triggered delivery of anticancer drugs [1–3] is mainly focused on the applications of 
the tumor microenvironmental or cellular physiological characteristics including higher 
temperature [4–5], lower pH [6–8], higher redox potential [9–11], enzyme overexpression 
[12–13] and higher level of reactive oxygen species [14–15] to promote the release of drugs 
at the target site for cancer treatment. Numerous nanocarriers integrating with the responsive 
elements, such as liposomes, polymeric nanoparticles, protein/DNA nanostructures and 
inorganic nanovehicles, have been widely exploited to achieve controlled release of their 
cargoes within the tumor tissues or cells [16–22].
Recently, adenosine-5′-triphosphate (ATP), the primary energy molecule for cell function, is 
attracting extensive attentions, which can be used as a promising trigger for enhanced 
release of preloaded drugs form the carriers responding to the intracellular ATP 
concentration [23–26]. ATP has a very high concentration inside the cells (1–10 mM), 
which is much greater than that outside the cells (< 5 μM) [27, 28]. Such a pronounced 
gradient is the premise of design of the ATP-triggered intracellular drug delivery systems. 
However, the existing ATP-responsive anticancer drug delivery methods are often limited 
by complicated formulation design and relatively low loading capacity of drugs [23, 24].
Herein, we present a new ATP-responsive anticancer drug delivery strategy utilizing DNA-
graphene crosslinked hybrid nanoaggregates as carriers (Fig. 1). This nanoaggregate consists 
of graphene oxide (GO), two single-stranded DNA (ssDNA, denoted as DNA1 and DNA2) 
and ATP aptamer. The GO nanosheet is applied to carry doxorubicin (DOX), a model small-
molecule anticancer drug, with a high loading efficiency via supramolecular π-π stacking 
between GO and DOX [29–34]. The single-stranded DNA1 and DNA2 together with the 
ATP aptamer serve as the linkers upon hybridization for controlled assembly of the DNA-
GO nanoaggregates (DNA-GA). Both DNA1 and DNA2 are composed of “head” and “tail” 
sequences, which are a target-specific sequence (the head one) complementary to the target 
ATP aptamer and a repeated GT sequence (the tail one) to facilitate the binding of DNA1 or 
DNA2 onto the GO nanosheets, respectively [35–37]. DNA1 and DNA2 are separately 
added to the DOX-loaded GO (DOX/GO) solution to form the DOX-loaded DNA-GO 
complex (DOX/DNA-GC) via strong interactions including van der Waals forces, π-π 
stacking and hydrogen bond [38, 39]. When the ATP aptamer is added into the mixture of 
DOX/DNA1-GC and DOX/DNA2-GC (DOX/DNA12-GC), the hybridization of the ATP 
aptamer with both DNA1 and DNA2 results in the assembly of the GO nanosheets to form 
the layered-structural DOX-loaded DNA-GO nanoaggregates (DOX/DNA-GA). Such 
aggregates, with an increased average size and a decreased specific surface area toward the 
surrounding medium [40, 41], can effectively inhibit DOX release from the GO nanosheets. 
The ATP aptamer has been widely used for ATP detection based on its specific and stable 
binding to ATP [42–44]. In the presence of ATP, the responsive formation of the ATP/ATP 
aptamer complex causes the dissociation of DOX/DNA-GA into DOX/DNA-GC that has a 
decreased size and an increased surface area exposing to the medium, which promotes the 
release of DOX in the environment with a high ATP concentration such as cytosol compared 
with that in the ATP-deficient extracellular fluid. This supports the development of a novel 
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ATP-responsive platform for targeted on-demand delivery of anticancer drugs inside 
specific cells.
2. Materials and methods
2.1. Materials
All chemicals unless mentioned were purchased from Sigma-Aldrich Co. LLC. All the DNA 
samples (sequence from 5′ to 3′), including DNA1 (GTG TGT GTG TGT GTG TGT GTG 
TGT GTG TGT ACC TTC CTC CGC), DNA2 (ACT CCC CCA GGT GTG TGT GTG 
TGT GTG TGT GTG TGT GTG TGT), ATP aptamer (ACC TGG GGG AGT ATT GCG 
GAG GAA GGT), control aptamer (ATT CTT TTT TAC AAT ACT CCC CCA GGT) and 
Cy3-labeled DNA2 (Cy3-DNA2, Cy3-ACT CCC CCA GGT GTG TGT GTG TGT GTG 
TGT GTG TGT GTG TGT), were purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA, USA). Doxorubicin hydrochloride was purchased from BIOTANG Inc. 
(Lexington, MA, USA).
2.2. Preparation of DNA-GO complex (DNA-GC)
DNA-GC was prepared by mixing DNA1 or DNA2 with GO. After ultrasonication for 1 h, 
GO (0.2 mg/mL) was incubated with DNA1 or DNA2 (2 μM) in the HEPES buffer (10 mM, 
pH 7.4) containing magnesium chloride (MgCl2) (1 mM) at room temperature for 1 h. To 
remove the unbound DNA1 or DNA2, the solution was centrifuged at 21000 × g for 1 h and 
the supernatant was discarded. The precipitated DNA-GC was then resuspended in the 
HEPES buffer (10 mM, pH 7.4) containing sodium chloride (NaCl) (100 mM). The particle 
size of DNA-GC was measured by a Zetasizer (Nano ZS, Malvern).
2.3. Preparation of DNA-GO aggregate (DNA-GA)
DNA-GA was prepared by incubating DNA1-GC and DNA2-GC with the ATP aptamer. 
DNA1-GC and DNA2-GC (500 μL) were mixed at the ratio of 1:1 in the HEPES buffer (10 
mM, pH 7.4) containing NaCl (100 mM), followed by adding the ATP aptamer (1 μM). The 
mixture solution was then incubated at room temperature for 24 h. The particle size of 
DNA-GA was measured by the Zetasizer. For atomic force microscope (AFM) 
characterization, the DNA-GA solution was dropped onto a mica substrate (Ted Pella). After 
air-dry, the sample was observed by AFM (NanoScope IIIa). To evaluate the ATP-
responsive dissociation of DNA-GA, DNA-GA was incubated with different concentrations 
of ATP, cytidine triphosphate (CTP) or guanosine triphosphate (GTP). The particle size was 
measured by the Zetasizer.
2.4. Fluorescence-based determination of formation and dissociation of DNA-GA
To explore the formation and ATP-responsive dissociation of DNA-GO aggregate, the 
fluorescence quenching/recovery measurements were applied on the basis of the interaction 
between GO and Cy3-DNA2. To investigate the effect of electrolytes on the adsorption 
efficiency of DNA onto the GO surface, Cy3-DNA2 (1.2 μM) was mixed with GO (0.1 
mg/mL) in the HEPES buffer containing different concentrations of NaCl or MgCl2 at room 
temperature for different time. The fluorescence intensity of Cy3 was measured at an 
emission wavelength of 580 nm with an excitation wavelength of 550 nm by a fluorescence 
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microplate reader (Infinite M200 PRO, Tecan). The fluorescence quenching efficiency 
((1−F/F0) × 100%) was determined, where F0 and F were the fluorescence intensities of 
Cy3 before and after Cy3-DNA2 was incubated with GO, respectively. To explore the 
formation of DNA-GA, DNA1 and Cy3-DNA2 (1.2 μM) was first mixed with GO (0.1 
mg/mL) in the HEPES buffer containing MgCl2 (1 mM) at room temperature for 1 h to 
obtain DNA1-GC and Cy3-DNA2-GC, respectively. Subsequently, DNA1-GC and Cy3-
DNA2-GC were mixed at the ratio of 1:1, followed by adding different concentrations of the 
ATP aptamer and incubating for different time. The fluorescence intensity of Cy3 was 
measured during the formation process of DNA-GA. The fluorescence recovery ratio (F/F0 
× 100%) was determined, where F0 and F were the fluorescence intensities of Cy3 before 
and after the mixture of DNA1-GC and Cy3-DNA2-GC (Cy3-DNA12-GC) was incubated 
with the ATP aptamer, respectively. To trace the ATP-triggered dissociation of DNA-GA, 
Cy3-DNA-GA was incubated with different concentrations of ATP or CTP for 30 min. The 
fluorescence intensity of Cy3 was measured during the disassembly process of Cy3-DNA-
GA. The fluorescence quenching efficiency ((1−F/F0) × 100%) was determined, where F0 
and F were the fluorescence intensities of Cy3 before and after Cy3-DNA-GA was 
incubated with ATP or CTP, respectively.
2.5. Preparation of DOX-loaded DNA-GA (DOX/DNA-GA)
To prepare DOX/GO, 40 μL of the dimethyl sulphoxide (DMSO) solution containing 
triethanolamine-treated DOX (5 mg/mL) was added dropwise into 10 mL of the GO solution 
(0.2 mg/mL) under vigorous stirring. After incubation at room temperature for 24 h, the 
solution was dialyzed against the deionized (DI) water to remove the triethanolamine, 
DMSO and the unbound DOX. The fluorescence spectra of DOX were scanned at an 
excitation wavelength of 480 nm by the fluorescence microplate reader. Subsequently, the 
preparation of DOX/DNA-GA was similar to that of DNA-GA except that DOX/GO was 
used to substitute the blank GO. The particle sizes of DOX/GO, DOX/DNA-GC and DOX/
DNA-GA were measured by the Zetasizer.
2.6. In vitro release of DOX
1 mL of DOX/DNA-GC or DOX/DNA-GA (20 μg/mL) was added into a dialysis tube (10K 
MWCO) (Slide-A-Lyzer, Thermo Scientific) against 14 mL of the HEPES buffer containing 
different concentrations of ATP, followed by gently shaking at 37 °C in a shaker (New 
Brunswick Scientific) at 100 rpm. At predetermined time intervals, the total buffer solution 
was sampled and replaced with 14 mL of the fresh buffer solution. The fluorescence 
intensity of DOX released was measured at an emission wavelength of 596 nm with an 
excitation wavelength of 480 nm by the fluorescence microplate reader.
2.7. Cell culture
The human cervical adenocarcinoma (HeLa) cells were cultured in DMEM with FBS (10%, 
v:v), penicillin (100 U/mL) and streptomycin (100 μg/mL) in a cell culture incubator 
(Thermo Scientific) at 37 °C under a condition of 5% CO2 and 90% relative humidity. The 
cells were sub-cultivated approximately every 3 days at 80% confluence using trypsin 
(0.25%, w:v) at a split ratio of 1:5.
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HeLa cells (1 × 105 cells/well) were seeded in 6-well plates. After culture for 48 h, the cells 
were incubated with DOX/DNA-GC or DOX/DNA-GA (4 μg/mL) at 4 and 37 °C for 2 h, 
respectively. The cells were then washed by ice-cold PBS twice and lyzed using the cell 
lysis buffer (Pierce, Thermo Scientific) at room temperature for 10 min. The cell lysate was 
collected and centrifuged at 14000 × g for 5 min. The fluorescence intensity of DOX in the 
cell lysate was measured at an emission wavelength of 596 nm with an excitation 
wavelength of 480 nm by the fluorescence microplate reader. The total protein concentration 
in the cell lysate was quantified using the BCA protein assay kit (Pierce, Thermo Scientific). 
The cellular uptake of DOX was calculated as UDOX = QDOX/Qprotein, where QDOX and 
Qprotein were the amounts of DOX and protein in the cells, respectively. The relative uptake 
efficiency was determined as the ratio of UDOX at 4 °C to that at 37 °C.
2.9. Intracellular release of DOX
HeLa cells (1 × 105 cells/well) were seeded in 6-well plates. After culture for 48 h, the cells 
were incubated with DOX/DNA-GA (4 μg/mL) at 37 °C for 2 h. The excessive DOX/DNA-
GC or DOX/DNA-GA was removed and the cells were incubated with the fresh FBS free 
culture medium at 4 or 37 °C for additional 1 or 2 h. The cells were washed by ice-cold PBS 
twice and harvested. The fluorescence intensity of DOX in the cells was measured using 
flow cytometry (BD FACSCalibur). The intracellular release rate of DOX was indicated as 
(Ft/F0 × 100%), where F0 is the fluorescence intensity of DOX in the cells after the first 2 h 
incubation with DOX/DNA-GA, and Ft is the fluorescence intensity of DOX in the cells 
after incubation for addition time periods (1 or 2 h) following the first 2 h incubation.
2.10. Intracellular distribution
HeLa cells (1 × 105 cells/well) were seeded in a confocal microscopy dish (MatTek). After 
culture for 24 h, the cells were incubated with DOX/DNA-GA (4 μg/mL) at 37 °C. At 
predetermined time intervals (2 and 6 h), the cells were washed by ice-cold PBS twice and 
then stained by Hoechst 33342 (1 μg/mL) (Life Technologies) at 37 °C for 10 min. The cells 
were then washed by ice-cold PBS twice and immediately observed using the confocal laser 
scanning microscope (CLSM) (LSM 710, Zeiss).
2.11. Cytotoxicity
HeLa cells (1 × 104 cells/well) were seeded in 96-well plates. After culture for 24 h, the 
cells were incubated with the DOX solution, DOX/DNA-GC or DOX/DNA-GA for 24 or 48 
h, followed by adding 20 μL of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution (5 mg/mL). After 4 h of incubation, the medium was removed, and 
the cells were mixed with 150 μL of DMSO. The absorbance was measured at a test 
wavelength of 570 nm and a reference wavelength of 630 nm by the microplate reader 
(Infinite M200 PRO, Tecan).
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3. Results and discussion
3.1. DNA-mediated assembly and ATP-triggered dissociation of GA
To explore the DNA-mediated assembly and ATP-triggered dissociation of DNA-GA, the 
particle size was determined using the dynamic laser scanning (DLS) measurement [35, 45–
47] (Fig. 2). After ultrasonication and purification, we obtained a well-dispersed GO sheet in 
water, which had an average particle size of 180 nm (Fig. 2a). DNA-GC was prepared by 
incubating the as-prepared GO nanosheets with DNA1 or DNA2 at a high salt condition 
[48], followed by centrifugation to remove the free DNA. The presence of DNA was able to 
enhance the stability of GO in a wider range of ionic strength. GO without DNA showed an 
increased particle size with the ionic strength, while DNA-GC exhibited a good stability 
even in the HEPES buffer solution containing a high concentration of NaCl (100 mM).
After incubating the mixture of DNA1-GC and DNA2-GC (DNA12-GC) with different 
concentrations of the ATP aptamer, the hybridization of DNA1 and DNA2 with the ATP 
aptamer resulted in an ATP aptamer concentration-dependent formation of nanoaggregates 
(Fig. 2b). DNA-GA showed a concomitant increase in the particle size with the 
concentration of the ATP aptamer. The average particle sizes of DNA-GA with the ATP 
aptamer concentration of 0.2 and 1 μM were 290 and 550 nm, respectively. To confirm that 
the interaction of the ATP aptamer with both DNA1 and DNA2 played an essential role in 
the assembly of DNA-GA, we applied a mismatched DNA as a control aptamer to examine 
the specificity of this process. Upon mixing DNA12-GC with the control aptamer, no 
significant changes were determined in the particle size of the mixture when varying the 
concentrations of the control aptamer. The mixture remained the particle size at 200 nm as 
the concentration of the control aptamer increased, suggesting that the ATP aptamer with the 
specific sequence could hybridize with DNA1 and DNA2, which associatively acted as a 
bridge to connect DNA-GC together for the formation of DNA-GA. We further applied DLS 
to monitor the DNA-mediated GO assembly process, which showed close association with 
the relative physical sizes of GA [35, 45–47].
The AFM imaging was applied to directly observe the structure conversion from DNA-GC 
to DNA-GA (Fig. 2c). From the AFM images, DNA-GC displayed a clear single-layer 
structure with the thickness of 2 nm, whereas the thickness of DNA-GA was 5–15 nm, with 
a well-packed layered structure. Such a notable increase in the thickness of GO was 
indicated to be closely associated with the DNA hybridization.
To investigate the ATP-responsive disassembly of DNA-GA, we incubated DNA-GA with 
different concentrations of ATP and monitored the particle size change (Fig. 2d). After 
incubating with ATP, as expected, the particle size of DNA-GA effectively reduced with the 
increase of the ATP concentration. In the existence of 3 mM ATP, DNA-GA showed an 
average particle size of 270 nm compared with DNA-GA without ATP of 550 nm. In 
addition, there was a remarkable difference in the particle size of DNA-GA after incubation 
with 3 and 0.3 mM ATP. To further evaluate the selectivity of the DNA-GA dissociation, 
the ATP analogues, CTP and GTP, were added into the DNA-GA solution, followed by the 
size measurement. The particle size change of DNA-GA at 3 mM ATP was significantly 
greater than that at 3 mM CTP or GTP. It was suggested that when DNA-GA was exposed 
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to a high level of ATP, the formation of ATP/ATP aptamer complex led to the dissociation 
of DNA-GA into DNA-GC with decreased particle sizes.
Furthermore, we utilized the fluorescence quenching and recovery measurements, based on 
the interaction between GO and Cy3-DNA2, to explore the ATP-aptamer-directed assembly 
and ATP-triggered disassembly of DNA-GA (Fig. 3) [49, 50]. The electrolytes including 
NaCl and MgCl2 were applied to screen the electrostatic repulsion between the polyanionic 
DNA and the negatively charged GO at neutral condition, which made DNA close to the GO 
surface for binding. After Cy3-DNA2 was incubated with the GO nanosheets at different 
concentrations of NaCl or MgCl2, the fluorescence of Cy3-DNA2 presented different 
degrees of quenching due to the emission from Cy3 to GO by förster resonance energy 
transfer (FRET), which indicated the adsorption of DNA onto the surface of the GO 
nanosheets (Fig. 3a and b). This quenching effect was enhanced by the increasing salt 
concentrations. The quenching efficiency of Cy3-DNA2 was less than 15% even at 24 h 
post-incubation with GO in the absence of the electrolytes, but about 58% at 100 mM NaCl 
and nearly 100% at 1 mM MgCl2 only after 15 min of incubation with GO. MgCl2 presented 
a stronger quenching capability than NaCl, which was attributed to the more effective 
capability of divalent metal ions than monovalent ones to shield charges for the connection 
of two negatively charged molecules [48].
The incubation of Cy3-DNA12-GC with the ATP aptamer attenuated the quenching effect 
of GO, thereby yielding the fluorescence recovery of Cy3 in a concentration-dependent 
manner (Fig. 3c), which was ascribed to the desorption of the dye from the GO surface upon 
the hybridization of the Cy3-labeled head sequence of DNA2 with the complementary one 
of the ATP aptamer. The fluorescence intensity of Cy3 significantly increased after 
treatment with different concentrations of the ATP aptamer in comparison with the untreated 
one, implying the assembly of DNA-GA. After the addition of ATP, Cy3-DNA-GA 
presented a reduction in the fluorescence intensity of Cy3 accompanied by the increase in 
the ATP concentration (Fig. 3d), since the efficient binding of ATP to the ATP aptamer 
resulted in the dehybridization between the ATP aptamer and Cy3-DNA2, followed by the 
re-adsorption of Cy3-DNA2 onto the surface of GO and the fluorescence re-quenching of 
Cy3 by GO. The fluorescence quenching efficiency of Cy3-DNA-GA with ATP was 
noticeably higher than that with the same concentration of CTP. Taken together, the 
fluorescence quenching, recovery and re-quenching of Cy3 validated the assembly and 
disassembly of DNA-GA in part.
3.2. Preparation and characterization of DOX/GA
DOX was efficiently loaded on the GO surface to obtain DOX/GO by the π-π stacking 
effect, the main interactions between the conjugated structure of the GO sheet and the 
quinone portion of DOX as well as the hydrophobic force between them [29–34]. The DOX-
loading capacity was about 10% as a mass ratio of DOX to GO. DOX/GO displayed a 
remarkable quenching effect of the DOX emission compared with free DOX after excitation 
at the same wavelength due to the FRET process along the interface of GO and DOX (Fig. 
4a). DOX loading had no influence on the formation of DNA-GA, which was also 
determined by monitoring the particle size change (Fig. 4b). The average particle size of 
Mo et al. Page 7













DOX/DNA-GA showed an ATP aptamer concentration-dependent increase, which was 585 
nm at the ATP aptamer concentration of 1 μM, significantly higher than 271 nm in the 
absence of the ATP aptamer. In addition, no obvious change in the particle size was 
observed in the presence of the untargeted control aptamer. The particle size remained about 
275 nm regardless of the concentration of the control aptamer. When exposed to high 
concentration of ATP (3 mM), the particle size of DOX/DNA-GA sharply dropped to 298 
nm, while neither CTP nor GTP with the same concentration of ATP showed such a strong 
effect on contributing to the dissociation of DOX/DNA-GA (Fig. 4c).
3.3. ATP-triggered DOX release
To assess the ATP-triggered DOX release property of DOX/DNA-GA, we determined the in 
vitro release profiles of DOX from DOX/DNA-GA in the presence and absence of different 
concentrations of ATP (Fig. 4d). Only 4.7% of DOX was released from DOX/DNA-GA 
within 24 h in the absence of ATP, which was due to the significantly decreased specific 
surface area interacting with surrounding medium compared with that of the original GO. 
The relatively low concentration of ATP did not accelerate the release of DOX. In the 
presence of 0.3 mM ATP, the 24 h cumulative DOX release ratio is about 5.4%. However, 
the release DOX was notably promoted, when DOX/DNA-GA was incubated in the same 
buffer solution containing 3 mM ATP that was comparable to the intracellular ATP 
concentration. DOX/DNA-GA exhibited approximately 6.1% of DOX released in the first 6 
h and more than 10% of DOX released within 24 h, which was similar to the DOX release 
behavior of DOX/DNA-GC. It was suggested that the ATP-responsive disassembly of DOX/
DNA-GA to DOX/DNA-GC resulted in the decreased particle size along with the increased 
specific surface area, thereby facilitating the release of DOX from the GO surface.
3.4. Intracellular ATP-responsive DOX release
To demonstrate the cellular internalization capability of DOX/DNA-GA, the uptake of 
DOX/DNA-GA at 37 and 4 °C were compared on HeLa cells. As shown in Fig. 5a, the 
cellular uptake of both DOX/DNA-GA and DOX/DNA-GC were dramatically inhibited at 4 
°C. The relative cellular uptake efficiency of DOX/DNA-GA was about 16%, indicating that 
DOX/DNA-GA entered into the cells via a typical endocytotic process [51, 52]. We next 
investigated the intracellular DOX release from DOX/DNA-GA by monitoring the 
fluorescence intensity of DOX in the cells (Fig. 5b). HeLa cells were incubated with DOX/
DNA-GA for 2 h. After completely removing the excess formulations, the cells were 
incubated with the fresh culture medium for an additional 1 or 2 h. The amount of released 
DOX was determined by monitoring the fluorescence intensity of the whole cells using flow 
cytometry. DOX/DNA-GA showed a concomitant increase of fluorescence intensity with 
the incubation time. The cells presented significant increase in the fluorescence intensity of 
DOX after another 1 and 2 h of incubation, respectively. To further confirm that the 
increased DOX release from DOX/DNA-GA was mediated by the intracellular ATP 
concentration, we impeded the ATP synthesis of the cells by reducing the temperature (4 
°C), and subsequently recorded the fluorescence intensity of the treated cells, after 2 h of 
incubation with DOX/DNA-GA. There was no significant increase in the release of DOX in 
the cells at 4 °C, which suggested the intracellular ATP-enhancing DOX release ability of 
DOX/DNA-GA.
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3.5. Intracellular distribution and cytotoxicity
The intracellular distribution was visualized using CLSM (Fig. 5c). DOX and the stained 
nuclei displayed red and blue fluorescence, respectively. After 2 h of incubation, DOX/
DNA-GA was endocytosed by the cancer cells and evenly distributed within the cells. As 
the incubation time was prolonged to 6 h, DOX was efficiently released from GO, and the 
released DOX was specifically accumulated into the nuclei for subsequently inducing 
cytotoxicity, as observed by the magenta fluorescence. The in vitro cytotoxicity of DOX/
DNA-GA toward the cancer cells was evaluated using the MTT assay (Fig. 5d and e). DOX/
DNA-GA presented an efficient and comparable cytotoxicity to DOX/DNA-GC against 
HeLa cells, indicating that the intracellular high ATP concentration resulted in the 
disintegration from DOX/DNA-GA to DOX/DNA-GC and therefore supported the parallel 
DOX release of DOX/DNA-GA with DOX/DNA-GC (Fig. 5d). Nevertheless, the free DOX 
solution showed the highest toxicity to HeLa cells under the same condition due to the 
partial inefficient release of DOX from the GO surface. The cytotoxicity of DOX/DNA-GA 
significantly increased when the incubation time increased (Fig. 5e), suggesting that the 
sustainedly released DOX from DOX/DNA-GA allowed the enhanced cytotoxic effect 
toward the cancer cells.
4. Conclusion
In summary, we have developed a new ATP-mediated controlled drug release system 
comprised of a 2D nanomaterial (GO) assembled nanoaggregates crosslinked by ATP-
responsive DNA strands. The straightforward formulation design, high loading capacity of 
drugs and capability of site-specifically promoting drug release render this formulation as a 
promising strategy for enhanced therapeutic efficacy in cancer treatment. It also provides 
innovative insights for taking advantages of 2D nanostructures for drug delivery through a 
reversible assembly fashion, which can be programmed by metabolic elements.
Acknowledgments
This work was supported by NC TraCS (grant 550KR51307), NIH’s Clinical and Translational Science Awards 
(CTSA, 1UL1TR001111) at UNC-CH, the NC State Faculty Research and Professional Development Award, and 
the start-up package from the Joint BME Department of UNC-CH and NCSU to Z.G.
References
1. Motornov M, Roiter Y, Tokarev I, Minko S. Stimuli-responsive nanoparticles, nanogels and 
capsules for integrated multifunctional intelligent systems. Prog Polym Sci. 2010; 35:174–211.
2. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013; 
12:991–1003. [PubMed: 24150417] 
3. Ge Z, Liu S. Functional block copolymer assemblies responsive to tumor and intracellular 
microenvironments for site-specific drug delivery and enhanced imaging performance. Chem Soc 
Rev. 2013; 42:7289–325. [PubMed: 23549663] 
4. Chen KJ, Liang HF, Chen HL, Wang Y, Cheng PY, Liu HL, et al. A thermoresponsive bubble-
generating liposomal system for triggering localized extracellular drug delivery. ACS Nano. 2013; 
7:438–46. [PubMed: 23240550] 
5. May JP, Ernsting MJ, Undzys E, Li SD. Thermosensitive liposomes for the delivery of gemcitabine 
and oxaliplatin to tumors. Mol Pharm. 2013; 10:4499–508. [PubMed: 24152292] 
Mo et al. Page 9













6. Takemoto H, Miyata K, Hattori S, Ishii T, Suma T, Uchida S, et al. Acidic pH-responsive siRNA 
conjugate for reversible carrier stability and accelerated endosomal escape with reduced IFNα-
associated immune response. Angew Chem Int Ed Engl. 2013; 52:6218–21. [PubMed: 23630117] 
7. Ju C, Mo R, Xue J, Zhang L, Zhao Z, Xue L, et al. Sequential intra-intercellular nanoparticle 
delivery system for deep tumor penetration. Angew Chem Int Ed Engl. 2014; 53:6253–8. [PubMed: 
24740532] 
8. Liu D, Zhang H, Herranz-Blanco B, Mäkilä E, Lehto VP, Salonen J, et al. Microfluidic assembly of 
monodisperse multistage pH-responsive polymer/porous silicon composites for precisely controlled 
multi-drug delivery. Small. 2014; 10:2029–38. [PubMed: 24616278] 
9. Wang X, Cai X, Hu J, Shao N, Wang F, Zhang Q, et al. Glutathione-triggered “off-on” release of 
anticancer drugs from dendrimer-encapsulated gold nanoparticles. J Am Chem Soc. 2013; 
135:9805–10. [PubMed: 23789713] 
10. Zhao M, Hu B, Gu Z, Joo KI, Wang P, Tang Y. Degradable polymeric nanocapsule for efficient 
intracellular delivery of a high molecular weight tumor-selective protein complex. Nano Today. 
2013; 8:11–20.
11. Chen W, Huang Q, Ou W, Hao Y, Wang L, Zeng K, et al. Self-reporting liposomes for 
intracellular drug release. Small. 2014; 10:1261–5.
12. Gu Z, Yan M, Hu B, Joo KI, Biswas A, Huang Y, et al. Protein nanocapsule weaved with 
enzymatically degradable polymeric network. Nano Lett. 2009; 9:4533–8. [PubMed: 19995089] 
13. Jiang T, Mo R, Bellotti A, Zhou J, Gu Z. Gel-liposome-mediated co-delivery of anticancer 
membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv 
Funct Mater. 2014; 24:2295–304.
14. Shim MS, Xia Y. A reactive oxygen species (ROS)-responsive polymer for safe, efficient, and 
targeted gene delivery in cancer cells. Angew Chem Int Ed Engl. 2013; 52:6926–9. [PubMed: 
23716349] 
15. de Gracia Lux C, Joshi-Barr S, Nguyen T, Mahmoud E, Schopf E, Fomina N, et al. Biocompatible 
polymeric nanoparticles degrade and release cargo in response to biologically relevant levels of 
hydrogen peroxide. J Am Chem Soc. 2012; 134:15758–64. [PubMed: 22946840] 
16. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging 
platform for cancer therapy. Nat Nanotechnol. 2007; 2:751–60. [PubMed: 18654426] 
17. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chem 
Soc Rev. 2011; 40:3638–55. [PubMed: 21566806] 
18. Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med. 2013; 
5:216rv4.
19. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for 
biology and medicine. Angew Chem Int Ed Engl. 2010; 49:3280–94. [PubMed: 20401880] 
20. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of multifunctional 
materials for biomedical applications. Chem Soc Rev. 2011; 40:44–56. [PubMed: 20818451] 
21. Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED, et al. Molecularly self-
assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012; 
7:389–93. [PubMed: 22659608] 
22. Jiang T, Sun W, Zhu Q, Burns NA, Khan SA, Mo R, et al. Furin-mediated sequential delivery of 
anticancer cytokine and small-molecule drug shuttled by graphene. Adv Mater. 201510.1002/
adma.201404498
23. Mo R, Jiang T, DiSanto R, Tai W, Gu Z. ATP-triggered anticancer drug delivery. Nat Commun. 
2014; 5:3364. [PubMed: 24618921] 
24. Mo R, Jiang T, Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. 
Angew Chem Int Ed Engl. 2014; 53:5815–20. [PubMed: 24764317] 
25. Naito M, Ishii T, Matsumoto A, Miyata K, Miyahara Y, Kataoka K. A phenylboronate-
functionalized polyion complex micelle for ATP-triggered release of siRNA. Angew Chem Int Ed 
Engl. 2012; 51:10751–5. [PubMed: 22907668] 
26. Biswas S, Kinbara K, Niwa T, Taguchi H, Ishii N, Watanabe S, et al. Biomolecular robotics for 
chemomechanically driven guest delivery fuelled by intracellular ATP. Nat Chem. 2013; 5:613–
20. [PubMed: 23787753] 
Mo et al. Page 10













27. Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, Ashcroft FM. A novel method for 
measurement of submembrane ATP concentration. J Biol Chem. 2000; 275:30046–9. [PubMed: 
10866996] 
28. Gorman MW, Feigl EO, Buffington CW. Human plasma ATP concentration. Clin Chem. 2007; 
53:318–25. [PubMed: 17185366] 
29. Yang K, Feng L, Shi X, Liu Z. Nano-graphene in biomedicine: theranostic applications. Chem Soc 
Rev. 2013; 42:530–47. [PubMed: 23059655] 
30. Yang X, Zhang X, Liu Z, Ma Y, Huang Y, Chen Y. High-efficiency loading and controlled release 
of doxorubicin hydrochloride on graphene oxide. J Phys Chem C. 2008; 112:17554–8.
31. Zhang L, Xia J, Zhao Q, Liu L, Zhang Z. Functional graphene oxide as a nanocarrier for controlled 
loading and targeted delivery of mixed anticancer drugs. Small. 2010; 6:537–44. [PubMed: 
20033930] 
32. Wang F, Liu B, Ip AC, Liu J. Orthogonal adsorption onto nano-graphene oxide using different 
intermolecular forces for multiplexed delivery. Adv Mater. 2013; 25:4087–92. [PubMed: 
23722422] 
33. Chen Y, Xu P, Shu Z, Wu M, Wang L, Zhang S, et al. Multifunctional graphene oxide-based triple 
stimuli-responsive nanotheranostics. Adv Funct Mater. 2014; 24:4386–4396.
34. Feng L, Li K, Shi X, Gao M, Liu J, Liu Z. Smart pH-responsive nanocarriers based on nano-
graphene oxide for combined chemo- and photothermal therapy overcoming drug resistance. Adv 
Healthcare Mater. 2014; 3:1261–1271.
35. Tang L, Wang Y, Liu Y, Li J. DNA-directed self-assembly of graphene oxide with applications to 
ultrasensitive oligonucleotide assay. ACS Nano. 2011; 5:3817–22. [PubMed: 21534537] 
36. Lv W, Guo M, Liang MH, Jin FM, Cui L, Zhi L, et al. Graphene-DNA hybrids: self-assembly and 
electrochemical detection performance. J Mater Chem. 2010; 20:6668–73.
37. Jin H, Jeng ES, Heller DA, Jena PV, Kirmse R, Langowski J, et al. Divalent ion and thermally 
induced DNA conformational polymorphism on single-walled carbon nanotubes. Macromolecules. 
2007; 40:6731–9.
38. Varghese N, Mogera U, Govindaraj A, Das A, Maiti PK, Sood AK, et al. Binding of DNA 
nucleobases and nucleosides with graphene. Chemphyschem. 2009; 10:206–10. [PubMed: 
18814150] 
39. Patil AJ, Vickery JL, Scott TB, Mann S. Aqueous stabilization and self-assembly of graphene 
sheets into layered bio-nanocomposites using DNA. Adv Mater. 2009; 21:3159–64.
40. Stankovich S, Dikin DA, Piner RD, Kohlhaas KA, Kleinhammes A, Jia Y, et al. Synthesis of 
graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon. 2007; 
45:1558–65.
41. Zhao B, Song J, Liu P, Xu W, Fang T, Jiao Z, et al. Monolayer graphene/NiO nanosheets with 
two-dimension structure for supercapacitors. J Mater Chem. 2011; 21:18792–8.
42. Liu JW, Lu Y. Smart nanomaterials responsive to multiple chemical stimuli with controllable 
cooperativity. Adv Mater. 2006; 18:1667–71.
43. Wang Y, Li Z, Hu D, Lin CT, Li J, Lin Y. Aptamer/graphene oxide nanocomplex for in situ 
molecular probing in living cells. J Am Chem Soc. 2010; 132:9274–6. [PubMed: 20565095] 
44. Meng HM, Zhang X, Lv Y, Zhao Z, Wang NN, Fu T, et al. DNA dendrimer: an efficient 
nanocarrier of functional nucleic acids for intracellular molecular sensing. ACS Nano. 2014; 
8:6171–81. [PubMed: 24806614] 
45. Hong BJ, Compton OC, An Z, Eryazici I, Nguyen ST. Successful stabilization of graphene oxide 
in electrolyte solutions: enhancement of biofunctionalization and cellular uptake. ACS Nano. 
2012; 6:63–73. [PubMed: 22017285] 
46. Tao Y, Lin Y, Ren J, Qu X. Self-assembled, functionalized graphene and DNA as a universal 
platform for colorimetric assays. Biomaterials. 2013; 34:4810–7. [PubMed: 23548641] 
47. Lin B, Sun Q, Liu K, Lu D, Fu Y, Xu Z, et al. Label-free colorimetric protein assay and logic gates 
design based on the self-assembly of hemin-graphene hybrid nanosheet. Langmuir. 2014; 
30:2144–51. [PubMed: 24559089] 
Mo et al. Page 11













48. Wu M, Kempaiah R, Huang PJ, Maheshwari V, Liu J. Adsorption and desorption of DNA on 
graphene oxide studied by fluorescently labeled oligonucleotides. Langmuir. 2011; 27:2731–8. 
[PubMed: 21302946] 
49. Huang PJ, Liu J. DNA-length-dependent fluorescence signaling on graphene oxide surface. Small. 
2012; 8:977–83. [PubMed: 22323437] 
50. Yang H, Paek K, Kim BJ. Efficient temperature sensing platform based on fluorescent block 
copolymer-functionalized graphene oxide. Nanoscale. 2013; 5:5720–4. [PubMed: 23712656] 
51. Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, et al. Mesoporous silica nanoparticles 
for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. 
Nanobiotechnology. 2007; 3:89–95. [PubMed: 19936038] 
52. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The targeted delivery 
of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat 
Mater. 2011; 10:389–97. [PubMed: 21499315] 
Mo et al. Page 12














Schematic illustration of ATP-responsive DNA-GA for controlled drug delivery.
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(a) The particle size of GO, DNA1-GC, DNA2-GC and DNA12-GC after incubation in the 
HEPES buffer containing different concentrations of NaCl for 24 h. (b) The particle size of 
the mixture of DNA1-GC and DNA2-GC after incubation with different concentrations of 
the ATP or control aptamer in the HEPES buffer containing 100 mM NaCl for 24 h. (c) The 
AFM images of DNA-GC and DNA-GA. The scale bars indicate 200 nm. (d) The particle 
size of DNA-GA after incubation with ATP, CTP and GTP in the HEPES buffer containing 
100 mM NaCl for 0.5 h.
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(a, b) The fluorescence quenching of Cy3-DNA2 after incubating Cy3-DNA2 with GO in 
the HEPES buffer containing different concentrations of NaCl (a) and MgCl2 (b) for 
different time. (c) The fluorescence recovery of Cy3-DNA2 after incubating the mixture of 
DNA1-GC and Cy3-DNA2-GC with different concentrations of the ATP aptamer in the 
HEPES buffer containing 1 mM MgCl2 for different time. (d) The fluorescence quenching 
of Cy3-DNA2 after incubating Cy3-DNA-GA with ATP and CTP in the HEPES buffer 
containing 1 mM MgCl2 for 0.5 h. *P < 0.05, ATP (3 mM) vs CTP (3 mM).
Mo et al. Page 15














(a) The fluorescence spectra of the DOX solution, DOX/GO and GO at the same excitation 
wavelength of 480 nm. (b) The particle size of the mixture of DOX/DNA1-GC and DOX/
DNA2-GC after incubation with different concentrations of the ATP or control aptamer in 
the HEPES buffer containing 100 mM NaCl for 24 h. (c) The particle size of DOX/DNA-
GA after incubation with ATP, CTP and GTP in the HEPES buffer containing 100 mM 
NaCl for 0.5 h. (d) The in vitro release profile of DOX/DNA-GA at different concentrations 
of ATP.
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(a) The relative cellular uptake efficiency of DOX/DNA-GC and DOX/DNA-GA on HeLa 
cells at 4 °C compared with 37 °C. **P < 0.01, 4 °C vs 37 °C. (b) The release of DOX from 
DOX/DNA-GA in HeLa cells obtained using flow cytometry. The DOX release ratio is 
determined by comparing the fluorescence intensity of DOX after 2 h of incubation with that 
after an additional 1or 2 h of incubation at 37 °C or 4 °C. (c) The CLSM images of HeLa 
cells after incubation with DOX/DNA-GC for 2 and 6 h. The nuclei were stained with 
Hoechst 33342. The scale bars indicate 20 μm. (d) The in vitro cytotoxicity of the DOX 
solution, DOX/DNA-GC and DOX/DNA-GA against HeLa cells after incubating for 48 h. 
(e) The in vitro cytotoxicity of DOX/DNA-GA against HeLa cells after incubating for 24 
and 48 h. *P < 0.05, **P < 0.01, 24 h vs 48 h.
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